Sign in

    Prem Lachman

    Research Analyst at MAXIMUS Capital

    Dr. Prem Lachman is the Founder, General Partner, and Portfolio Manager at Maximus Capital, a healthcare hedge fund specializing in pharmaceutical, biotechnology, medical device, and managed care sectors. He has covered major companies in these industries, such as OPKO Health, and served as co-portfolio manager for Galleon Group's multi-billion dollar healthcare fund, consistently earning recognition like #1 Institutional Investor All-Star Research Team at Goldman Sachs. His investment calls and sector research have delivered high performance, backed by more than 35 years of experience in portfolio management and investment research. Dr. Lachman began his career in equity research at County NatWest USA, was Managing Director and Head of Global Healthcare Equity Research at Goldman Sachs from 1989 to 1998, led healthcare at Galleon Group from 1998 to 2001, and founded Maximus Capital in 2001; he holds an M.D. from Mount Sinai and a B.A. in Economics from Columbia University, with numerous board roles at OPKO Health and leadership in major cultural institutions.

    Prem Lachman's questions to Legend Biotech (LEGN) leadership

    Prem Lachman's questions to Legend Biotech (LEGN) leadership • Q4 2024

    Question

    An analyst from MAXIMUS Capital sought clarification on the quarterly growth outlook for the year and comfort with consensus estimates. He also asked about market dynamics versus a new competitor in 2026 and how Legend plans to maintain its market share.

    Answer

    An Unknown Executive confirmed the outlook for sequential growth each quarter, with a significant step-up in Q2, and expressed confidence in doubling commercial supply. Regarding 2026 competition, the executive stated that by then, the overwhelming majority of revenue will be from the second- to fourth-line setting, where CARVYKTI is well-positioned with unmatched CR rates and an overall survival benefit, which they expect to be added to the label.

    Ask Fintool Equity Research AI